Jones Trading Rates Alterity Therapeutics (ATHE) buy

On June 30, 2026, Jones Trading reiterated its buy rating for Alterity Therapeutics with a $16 price target, a 197.95% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 10:01 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Jones Trading rated Alterity Therapeutics Limited ($ATHE) "buy" with a $16 price target on June 30, 2026.

Since the rating, $ATHE is up 2.2% after 1 week, down 16.2% after 1 month and down 51.2% to date (from the $5.37 close on Jun 30, 2026).

ATHE Alterity Therapeutics Limited

$2.62 -17.09% year to date

Daily close · Oct 16, 2026

Key Points

Jones Trading reiterated a buy rating on Alterity Therapeutics (NasdaqCM:ATHE) with a $16 target on June 30, 2026.
Jones Trading's $16 price target implies 197.95% upside from Alterity Therapeutics Limited's ($ATHE) current $5.37 share price.
Alterity Therapeutics traded near $4.89 on Tuesday, with a market cap of about $87.4 million and a 52-week range of $2.66 to $7.00.
Insiders Julian Michael Babarczy and Lawrence Bernard Gozlan bought 2 million and 1 million shares respectively on June 15, 2026.

Get $ATHE trade alerts by text

We text you when insiders, Congress or big funds trade $ATHE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Alterity Therapeutics Limited alert may contain errors. Disclosures

On June 30, 2026, Jones Trading reiterated its buy rating for Alterity Therapeutics Limited (NasdaqCM:ATHE), setting a price target of $16. The analyst, Debanjana Chatterjee, maintained her positive outlook on the biotechnology company.

Analyst rating track record

Jones Trading vs. the S&P 500

YTD return +61.39% hypothetical

All-time return +169.77% S&P 500 +31.55%

vs. S&P 500 +138.22% ahead of the index

Hypothetical returns from Jones Trading's disclosed trades, not real profit or advice. How we model this.

Alterity Therapeutics Limited Stock Up 37.0%

Shares of Alterity Therapeutics traded near $4.89 on Tuesday. The company, which is involved in developing treatments for Parkinsonian and neurodegenerative disorders, has a market cap of approximately $87.4 million. It has a 52-week low of $2.66 and a high of $7.00. The stock's 50-day moving average is $4.45, and the 200-day moving average is $3.89. Despite having a negative forward P/E ratio of -4.08 due to lack of profitability, the company boasts a strong current ratio of 21.98 and a quick ratio of 21.68, indicating solid liquidity.

12-month forecast

$ATHE price target

Alterity Therapeutics Limited daily closes and this analyst's $16 target. Not advice.

Insider Buying and Selling at Alterity Therapeutics Limited

Insider activity at Alterity Therapeutics saw significant buying on June 15, 2026. Julian Michael Babarczy acquired 2 million shares, while Lawrence Bernard Gozlan purchased 1 million shares. These transactions did not involve any planned trading arrangements.

Analysts Set New Price Targets

On June 30, 2026, Jones Trading reiterated its buy rating for Alterity Therapeutics, setting a price target of $16. Previously, on June 16, 2026, Ladenburg Thalmann assumed coverage with a buy rating and a $10 target. Maxim Group maintained its buy rating with a $12 target on January 30, 2025. The consensus among analysts is a strong buy, with a mean target price of $11.

About Alterity Therapeutics

Alterity Therapeutics Limited, headquartered in Melbourne, Australia, focuses on the research and development of treatments for neurodegenerative diseases, including Parkinson's disease and Multiple System Atrophy. Led by CEO Dr. David A. Stamler, the company is advancing its lead drug candidate, ATH434, through Phase II clinical trials. With a small team of just nine employees, Alterity is also working on developing additional compounds to address neurological conditions.

Bottom Line

Jones Trading's reiteration of a buy rating for Alterity Therapeutics highlights ongoing confidence in the company's future prospects. Shares were trading near $4.89, reflecting the market's current valuation. Investors often follow such analyst updates to gauge potential stock performance. As always, it's important to remember that these ratings reflect past analyses and may not indicate current positions.